Ulcerative Colitis Supplements: What the Trials Actually Show
Ulcerative colitis (UC) is a chronic disease that inflames the lining of the large intestine. It needs medical care, and it follows its own course. Supplements can sit alongside that care as adjuncts, never as replacements. This guide gives the doses human trials actually used, separates active disease from remission, and says plainly where the evidence is thin. Talk to your gastroenterologist before starting or stopping anything.
The short answer: what has the most evidence
Here is the ranked picture, from strongest human evidence to weakest.
- Curcumin. The strongest human evidence in UC. Gram doses of curcuminoid extract were studied as an adjunct to mesalamine in both remission and active mild to moderate disease.
- Probiotics, by strain. The evidence belongs to specific strains, not to the category. E. coli Nissle 1917 has maintenance data. VSL#3 has induction data in mild to moderate active UC and in pouchitis.
- Vitamin D. Worth testing and correcting if low. It is not a UC drug, and the trial results are modest.
- Omega-3 fats. Mixed overall. One specific EPA free fatty acid product showed a signal. General fish oil has not held up for maintenance.
- Butyrate and fiber. Emerging. Oral butyrate is promising but small. Plantago ovata fiber has real maintenance data.
The pattern is clear: the dose, the form, and the setting matter more than the label on the bottle. If you also want background on irritable bowel syndrome, which is a different condition from inflammatory bowel disease, our IBS supplements guide explains that separate set of options.
How we graded the evidence
A supplement trial is not a drug trial. Many UC supplement studies are small, single-center, and short. They use different endpoints. Clinical remission means symptoms have settled. Endoscopic remission means the lining looks healed on a scope. A calprotectin drop is a lab marker, and calprotectin is a protein in stool that rises when the gut lining is inflamed. Those are not the same result.
Most trials test the supplement alongside standard medicine, not instead of it. That is the right design for safety, but it means the supplement is an add-on. A result can also be statistically significant and still be small in real life. We graded each section by the size and quality of the human evidence, and we say when a finding is uncertain.
Small, positive trials are a reason to ask your GI, not a reason to change your prescription.
Curcumin: the strongest supplement evidence in UC
Curcumin is the yellow compound in turmeric. It has the deepest human trial base of the supplements reviewed here. The trials used extracts at gram doses, not spice.
The maintenance trial
The Hanai trial enrolled 89 people with quiescent UC, meaning symptoms were quiet. They took 2 g of curcumin per day, split as 1 g after breakfast and 1 g after the evening meal, plus sulfasalazine or mesalamine, for 6 months. Relapse occurred in 2 of 43 people on curcumin (4.65 percent) and 8 of 39 on placebo (20.51 percent), P = .040 [1]. That is a large difference in a small trial, and it made curcumin the supplement to beat.
The active disease trial
The Lang trial enrolled 50 people with active mild to moderate UC, all already on mesalamine. They added 3 g of curcumin per day for 1 month. Clinical remission occurred in 14 of 26 (53.8 percent) versus 0 of 24 on placebo, P = .01. Endoscopic remission was 38 percent versus 0 percent [2]. The direction is consistent, but the trial was small and short.
What the meta-analyses add
Yin 2022 pooled 6 trials and 385 participants [3]. Clinical remission favored curcumin, with a risk ratio of 2.10 (95 percent CI 1.13 to 3.89). Endoscopic outcomes were not statistically significant. Peng 2025 pooled 8 trials and 482 patients and found a risk ratio of 2.33 (95 percent CI 1.25 to 4.34) for clinical remission [4]. It found only a trend for endoscopic remission, plus a signal that higher doses did more. An earlier 2020 systematic review by Coelho and colleagues also framed curcumin as a complementary therapy rather than a stand-alone one [5]. The symptom signal is consistent. The endoscopy signal is weaker.
Form and dose
The trials used curcuminoid extracts at 2 to 3 g per day. Theracurmin, BCM-95, and Meriva are different delivery systems. They are not interchangeable milligram for milligram, because absorption differs. Match the total curcuminoids on the label, and ask your prescriber which form fits the evidence. Our curcumin benefits guide explains the forms in more detail.
One separate trial, Ben-Horin 2024, tested a combination of curcumin plus QingDai at 3 g per day. Clinical response was 85.7 percent versus 30.7 percent, and remission was 50 percent versus 8 percent [6]. That result belongs to the combination, not to curcumin alone.
Curcumin was well tolerated in these trials [5]. In theory it can affect how some drugs are broken down and can add to bleeding risk. If you take an anticoagulant or an immunosuppressant, ask your gastroenterologist before you start.
Omega-3: mixed results, one promising form
The overall picture is mixed, and the form matters.
A 2011 systematic review and meta-analysis by Turner and colleagues looked at fish oil for maintaining remission in inflammatory bowel disease [7]. In UC it found no maintenance benefit. The relapse risk ratio was 1.02, and diarrhea and upper GI side effects were more common. General fish oil is not a maintenance treatment for UC.
Scaioli 2018 tested something narrower: EPA free fatty acid, 500 mg twice daily for 6 months, in 60 people with UC at risk of relapse who were already on stable therapy. A calprotectin drop of 100 points occurred in 63.3 percent versus 13.3 percent. Clinical remission was maintained in 76.7 percent versus 50 percent [8]. That is a specific form at a specific dose, not a claim for any fish oil capsule.
Hawthorne 1992 added 4.5 g of EPA per day to standard drug therapy. It found a modest steroid-sparing effect in active disease, but no maintenance benefit [9].
Fish oil may still be worth taking for general cardiovascular and joint support [10]. Do not expect it to keep UC in remission on its own. Our omega-3 benefits guide covers dosing and forms.
Probiotics: the strain is the evidence
The category is not the evidence. The strain is.
Cochrane 2020 pooled 12 studies and 1,473 participants [11]. It found the evidence for maintenance uncertain, at low to very low certainty, with no clear difference from placebo or from 5-ASA, the drug class that includes mesalamine. That does not mean probiotics do nothing. It means most products have not been tested well enough to say.
E. coli Nissle 1917 is the exception with the clearest maintenance data. Kruis 1997 compared it with mesalamine in 120 people over 12 weeks and found it equivalent for maintenance [12]. A 2016 review notes that ECCO, the European Crohn's and Colitis Organisation, lists it as an alternative to mesalamine for maintenance [30].
VSL#3 has evidence for induction in mild to moderate active UC [31] and for maintenance in chronic pouchitis [32]. A 2026 trial in people with UC and IBS-like symptoms was negative on its primary endpoint, but it showed a signal for abdominal pain and bloating [13]. That is a hint, not a headline.
A generic probiotic is not interchangeable with the studied strains. If your goal is maintenance, the strain and the trial matter. Do not stop mesalamine to take a probiotic. Our guide to choosing a probiotic explains how to read a label.
Vitamin D: correct the deficiency, do not expect a drug
Vitamin D deficiency is common in UC. Test 25(OH)D, the standard blood test, rather than guessing.
Guan 2022 pooled 7 trials and 539 people [14]. Vitamin D supplementation improved vitamin D levels, ESR, and CRP, but the certainty was low to very low. Ahamed 2019 gave oral nano vitamin D3 at 60,000 IU per day for 8 days to people with active UC and vitamin D under 40 ng/mL [15]. A 3-point UCDAI reduction occurred in 53 percent versus 13 percent, and people who reached 40 ng/mL did better. Karimi 2020 compared 2,000 IU per day with 1,000 IU per day for 12 weeks and found less of an increase in some inflammatory markers at the higher dose [16]. Valvano 2024 found a lower relapse risk overall, but the UC subgroup was small and not significant, with a stronger signal in Crohn's disease [17].
Correct a deficiency, recheck it, and do not use vitamin D as a substitute for UC medication. Our vitamin D3 and K2 guide covers testing and safe dosing.
Butyrate and fiber: promising, not proven
Oral microencapsulated sodium butyrate is the emerging form. Golea 2026 reviewed 22 studies and reported encouraging adjunctive effects on clinical remission and inflammatory markers [18]. The clinical evidence is still early and heterogeneous.
Butyrate enemas are mixed. Jamka 2021 reviewed the randomized trials and concluded the evidence does not support enemas [19]. Steinhart 1996 was negative [20], and Scheppach 1992 was positive in a very small single-blind trial [21].
Plantago ovata seeds, 10 g twice daily, matched mesalamine for 12-month maintenance in a 105-person trial by Fernández-Bañares and colleagues in 1999 [22]. This fiber ferments to butyrate. It is not a substitute for mesalamine, but it is a reasonable adjunct with real trial data. During an active flare, bulky fiber can worsen gas, cramping, and bloating. Build slowly in remission.
Other herbs with small trials
Aloe vera gel, 100 mL twice daily for 4 weeks, was tested in a small placebo-controlled trial. Clinical remission occurred in 30 percent versus 7 percent, a difference that did not reach significance, and response occurred in 47 percent versus 14 percent [23]. Sigmoidoscopic scores did not differ. Andrographis paniculata extract, 1,800 mg per day for 8 weeks, was associated with a clinical response in 60 percent versus 40 percent in a placebo-controlled trial, but remission was not statistically significant [24]. Boswellia serrata has small trials, and one review described it as similar to mesalamine [25]. Wheatgrass juice has only limited data.
For a broader view, Ng 2013 [25] and Langhorst 2015 [26] reviewed the herbal and complementary literature. These are small signals from small trials. They are not a plan you can build on without your GI.
What to skip, and what not to expect
Glutamine has little human randomized trial evidence in UC. Generic immune support or detox products have little or no UC trial evidence, and some can interact with immunosuppressants. Megadose vitamins without a documented deficiency are unlikely to help, and high doses can be harmful. NSAIDs for pain may trigger flares in some people, so ask your GI first [27]. Culinary turmeric is not a trial dose. A sprinkle of spice cannot match 2 to 3 g of a curcuminoid extract.
Nutrient gaps that are worth testing
UC can leave real nutrient gaps. Test before you supplement, and treat the result rather than the symptom. Guidance from the NHS on UC treatment focuses on correcting calcium and vitamin B12 when they are low [27].
- Iron and ferritin. Anemia from blood loss is common. A CBC and a ferritin test show the picture.
- Vitamin B12. Risk is higher with ileal disease or ileal resection.
- Folate. Sulfasalazine can impair folate absorption [33].
- Calcium and vitamin D. Bone loss is a concern, especially with corticosteroid use.
- Magnesium and potassium. Losses can occur with chronic diarrhea.
These are correction targets, not UC treatments. Your GI or dietitian can confirm which ones apply. Our digestion and gastrointestinal support collection lists the products we stock for these gaps.
How this fits with your medication
Do not stop or reduce your UC medication to try a supplement. That is the one rule that does not bend.
Tell your gastroenterologist and your pharmacist about every supplement you take. Bring the label, because doses and forms vary. Ask about interactions, especially if you take an anticoagulant, an immunosuppressant, or a medicine with a narrow therapeutic window. Flare management belongs to your gastroenterologist. A supplement is not a rescue plan.
Call your care team promptly for heavy bleeding, fever, severe pain, signs of dehydration, or a flare that is not settling.
Diet still matters. A 2024 Mediterranean diet trial by Erol Doğan and colleagues found improved disease activity and quality of life within groups, but no significant difference between diet alone and diet plus curcumin or resveratrol [28]. Diet is foundational, not a replacement for treatment. The Crohn's and Colitis Foundation also recommends talking with your care team before adding complementary products [29].
What We Recommend
Integrative Therapeutics, Theracurmin HP 120 Veg Capsules
High-absorption curcumin for general curcumin support; the curcuminoid extract trials described above used 2 to 3 g per day, so match total curcuminoids with your GI rather than assuming milligram equivalence.
$93.50
XYMOGEN, CurcuPlex-95™ 120 Capsules
BCM-95 curcuminoid extract standardized to 95 percent curcuminoids, similar in form to the extracts used in the trials and intended for general curcumin support, though the serving still has to be matched to the studied dose with your GI.
$101.99
Integrative Therapeutics, Pure Omega Ultra HP 90 Softgels
High-potency EPA and DHA for general omega-3 support; the positive UC trial used a specific EPA free fatty acid at 1 g per day, not this oil, so it is support, not a maintenance drug.
$69.25
Allergy Research Group, ButyrEn 100 Delayed-Release Vegetarian Capsules
Delayed-release butyric acid; oral butyrate evidence is emerging and the enema evidence is mixed.
$24.19
Frequently Asked Questions
Can supplements replace my UC medication?
No. The trials described here tested supplements alongside standard medicine, mostly mesalamine. None of them supports stopping or reducing your prescription. Stopping UC medication on your own can lead to a flare.
What is the best dose of curcumin?
The human trials used 2 g per day for maintenance and 3 g per day for active disease, as curcuminoid extracts. Absorption differs between forms such as Theracurmin, BCM-95, and Meriva, so match total curcuminoids and ask your GI or pharmacist.
Are probiotics worth it?
Only when the strain matches the evidence. E. coli Nissle 1917 has maintenance data, and VSL#3 has induction data in mild to moderate active UC [31] and maintenance data in chronic pouchitis [32]. A generic probiotic is not interchangeable with those products.
Does fish oil help?
The overall evidence for maintenance is negative, with a relapse risk ratio of 1.02 in a 2011 meta-analysis. One specific EPA free fatty acid product, 500 mg twice daily, showed a calprotectin and remission signal. General fish oil is not a maintenance drug.
How much vitamin D?
Test 25(OH)D first. Correction doses in the trials ranged from 2,000 IU per day to 60,000 IU per day for 8 days under supervision. Do not megadose without a test and a plan from your care team.
Is fiber safe during a flare?
Bulky fiber can worsen gas, cramping, and bloating during an active flare. Plantago ovata has maintenance data in remission. Build fiber slowly when symptoms are quiet, and ask your GI if you are unsure.
What about aloe vera?
A small trial found a signal, but the scope scores did not differ. It used 100 mL of aloe vera gel twice daily for 4 weeks and found a higher response rate than placebo; the remission difference did not reach significance. Ask your GI before trying it.
When should I call my doctor?
Call promptly for heavy bleeding, fever, severe pain, signs of dehydration, or a flare that is not settling. Also call before starting any new supplement if you take an anticoagulant, an immunosuppressant, or multiple medicines.
References
- Hanai H, Iida T, Takeuchi K, et al. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clinical Gastroenterology and Hepatology. 2006. PMID 17101300. https://pubmed.ncbi.nlm.nih.gov/17101300/
- Lang A, Salomon N, Wu JC, et al. Curcumin in combination with mesalamine induces remission in patients with mild-to-moderate ulcerative colitis in a randomized controlled trial. Clinical Gastroenterology and Hepatology. 2015. PMID 25724700. https://pubmed.ncbi.nlm.nih.gov/25724700/
- Yin J, Wei L, Wang N, et al. Efficacy and safety of adjuvant curcumin therapy in ulcerative colitis: a systematic review and meta-analysis. Journal of Ethnopharmacology. 2022. PMID 35091013. https://pubmed.ncbi.nlm.nih.gov/35091013/
- Peng Z, Li D, Wu N, et al. Safety and efficacy of curcumin in the treatment of ulcerative colitis: an updated systematic review and meta-analysis of randomized controlled trials. Explore (New York). 2025. PMID 39612780. https://pubmed.ncbi.nlm.nih.gov/39612780/
- Coelho MR, Romi MD, Ferreira DMTP, et al. The use of curcumin as a complementary therapy in ulcerative colitis: a systematic review of randomized controlled clinical trials. Nutrients. 2020. PMID 32751776. https://pubmed.ncbi.nlm.nih.gov/32751776/
- Ben-Horin S, Salomon N, Karampekos G, et al. Curcumin-QingDai combination for patients with active ulcerative colitis: a randomized, double-blinded, placebo-controlled trial. Clinical Gastroenterology and Hepatology. 2024. PMID 37302449. https://pubmed.ncbi.nlm.nih.gov/37302449/
- Turner D, Shah PS, Steinhart AH, et al. Maintenance of remission in inflammatory bowel disease using omega-3 fatty acids (fish oil): a systematic review and meta-analyses. Inflammatory Bowel Diseases. 2011. PMID 20564531. https://pubmed.ncbi.nlm.nih.gov/20564531/
- Scaioli E, Sartini A, Bellanova M, et al. Eicosapentaenoic acid reduces fecal levels of calprotectin and prevents relapse in patients with ulcerative colitis. Clinical Gastroenterology and Hepatology. 2018. PMID 29391271. https://pubmed.ncbi.nlm.nih.gov/29391271/
- Hawthorne AB, Daneshmend TK, Hawkey CJ, et al. Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial. Gut. 1992. PMID 1353742. https://pubmed.ncbi.nlm.nih.gov/1353742/
- National Institutes of Health, Office of Dietary Supplements. Omega-3 Fatty Acids Fact Sheet for Health Professionals. Accessed 2026. https://ods.od.nih.gov/factsheets/Omega3FattyAcids-HealthProfessional/
- Iheozor-Ejiofor Z, Kaur L, Gordon M, et al. Probiotics for maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews. 2020. PMID 32128794. https://pubmed.ncbi.nlm.nih.gov/32128794/
- Kruis W, Schütz E, Fric P, et al. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Alimentary Pharmacology and Therapeutics. 1997. PMID 9354192. https://pubmed.ncbi.nlm.nih.gov/9354192/
- Borruel Sainz N, Serra-Ruiz X, Guarner Aguilar F, et al. VSL#3 may reduce abdominal pain and bloating in ulcerative colitis remission with IBS-like symptoms: an exploratory randomized, double-blind placebo-controlled trial. Nutrients. 2026. PMID 42514326. https://pubmed.ncbi.nlm.nih.gov/42514326/
- Guan Y, Hao Y, Guan Y, et al. Effects of vitamin D supplementation on blood markers in ulcerative colitis patients: a systematic review and meta-analysis. European Journal of Nutrition. 2022. PMID 34075433. https://pubmed.ncbi.nlm.nih.gov/34075433/
- Ahamed ZR, Dutta U, Sharma V, et al. Oral nano vitamin D supplementation reduces disease activity in ulcerative colitis: a double-blind randomized parallel group placebo-controlled trial. Journal of Clinical Gastroenterology. 2019. PMID 31356558. https://pubmed.ncbi.nlm.nih.gov/31356558/
- Karimi S, Tabataba-Vakili S, Ebrahimi-Daryani N, et al. Inflammatory biomarkers response to two dosages of vitamin D supplementation in patients with ulcerative colitis: a randomized, double-blind, placebo-controlled pilot study. Clinical Nutrition ESPEN. 2020. PMID 32220372. https://pubmed.ncbi.nlm.nih.gov/32220372/
- Valvano M, Magistroni M, Cesaro N, et al. Effectiveness of vitamin D supplementation on disease course in inflammatory bowel disease patients: systematic review with meta-analysis. Inflammatory Bowel Diseases. 2024. PMID 36579768. https://pubmed.ncbi.nlm.nih.gov/36579768/
- Golea GI, Ilieș RA, Caziuc A, et al. Sodium butyrate therapy in ulcerative colitis: a systematic review of preclinical and clinical evidence. Medical Sciences (Basel). 2026. PMID 42646603. https://pubmed.ncbi.nlm.nih.gov/42646603/
- Jamka M, Kokot M, Kaczmarek N, et al. The effect of sodium butyrate enemas compared with placebo on disease activity, endoscopic scores, and histological and inflammatory parameters in inflammatory bowel diseases: a systematic review of randomised controlled trials. Complementary Medicine Research. 2021. PMID 33352566. https://pubmed.ncbi.nlm.nih.gov/33352566/
- Steinhart AH, Hiruki T, Brzezinski A, et al. Treatment of left-sided ulcerative colitis with butyrate enemas: a controlled trial. Alimentary Pharmacology and Therapeutics. 1996. PMID 8899080. https://pubmed.ncbi.nlm.nih.gov/8899080/
- Scheppach W, Sommer H, Kirchner T, et al. Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis. Gastroenterology. 1992. PMID 1612357. https://pubmed.ncbi.nlm.nih.gov/1612357/
- Fernández-Bañares F, Hinojosa J, Sánchez-Lombraña JL, et al. Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. American Journal of Gastroenterology. 1999. PMID 10022641. https://pubmed.ncbi.nlm.nih.gov/10022641/
- Langmead L, Feakins RM, Goldthorpe S, et al. Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis. Alimentary Pharmacology and Therapeutics. 2004. PMID 15043514. https://pubmed.ncbi.nlm.nih.gov/15043514/
- Sandborn WJ, Targan SR, Byers VS, et al. Andrographis paniculata extract (HMPL-004) for active ulcerative colitis. American Journal of Gastroenterology. 2013. PMID 23044768. https://pubmed.ncbi.nlm.nih.gov/23044768/
- Ng SC, Lam YT, Tsoi KK, et al. Systematic review: the efficacy of herbal therapy in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics. 2013. PMID 23981095. https://pubmed.ncbi.nlm.nih.gov/23981095/
- Langhorst J, Wulfert H, Lauche R, et al. Systematic review of complementary and alternative medicine treatments in inflammatory bowel diseases. Journal of Crohn's and Colitis. 2015. PMID 25518050. https://pubmed.ncbi.nlm.nih.gov/25518050/
- National Health Service. Ulcerative colitis: treatment. Accessed 2026. https://www.nhs.uk/conditions/ulcerative-colitis/treatment/
- Erol Doğan Ö, Karaca Çelik KE, Baş M, et al. Effects of Mediterranean diet, curcumin, and resveratrol on mild-to-moderate active ulcerative colitis: a multicenter randomized clinical trial. Nutrients. 2024. PMID 38794742. https://pubmed.ncbi.nlm.nih.gov/38794742/
- Crohn's and Colitis Foundation. Complementary Medicine and Alternative Therapies. Accessed 2026. https://www.crohnscolitisfoundation.org/patientandcaregivers/complementary-medicine
- Scaldaferri F, Gerardi V, Mangiola F, et al. Role and mechanisms of action of Escherichia coli Nissle 1917 in the maintenance of remission in ulcerative colitis patients: an update. World Journal of Gastroenterology. 2016. PMID 27350728. https://pubmed.ncbi.nlm.nih.gov/27350728/
- Ma Y, Yang D, Huang J, et al. Probiotics for inflammatory bowel disease: is there sufficient evidence? Open Life Sciences. 2024. PMID 38585636. https://pubmed.ncbi.nlm.nih.gov/38585636/
- Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000. PMID 10930365. https://pubmed.ncbi.nlm.nih.gov/10930365/
- National Institutes of Health, Office of Dietary Supplements. Folate Fact Sheet for Health Professionals. Accessed 2026. https://ods.od.nih.gov/factsheets/Folate-HealthProfessional/
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
